ERBB2 and ductal breast carcinoma in situ: p-Akt is associated with resistance to hormonal treatment in metastatic breast cancer [12], and its expression is significantly higher in ER-positive/HER2-negative ductal carcinoma in situ (DCIS) adjacent to invasive breast cancer (IBC) than pure DCIS [13].